J&J Medical Connect
Neuroscience
Neuroscience

Congress Materials - Psych Congress 2026

 

2026 Psych Congress |Sep 15-19 | New Orleans, LA 

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: A Pooled Analysis of Efficacy Across Patient-Reported Depression Symptoms

Michael E. Thase, Ibrahim Turkoz, Brian Curcio, Kristin R. Dorsey, Hank Zhang, Manish K. Jha


This document will be available on Sep 17th 2026

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms

Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Alvin B. Oung, Rakesh Jain


This document will be available on Sep 17th 2026

Assessment of Lumateperone Partial Agonist Activity at Presynaptic Dopamine D2 Autoreceptors: Reversal of Haloperidol-induced Tyrosine Hydroxylase Phosphorylation in Mouse Striatum

Gretchen L. Snyder, Sophie Dutheil


This document will be available on Sep 17th 2026

Change in the Mean Total Score of the Patient Health Questionnaire-9 among Bipolar Depression Patients treated with Lumateperone in the United States: An Electronic Health Records Study

Namjoshi, Madhav; Black, Danae; Rasouliyan, Lawrence; Obando, Camilo


This document will be available on Sep 17th 2026

Efficacy of Adjunctive Lumateperone in Patients With Major Depressive Disorder: A Pooled Post Hoc Analysis of Patients With Clinical Features Associated With a More Challenging Disease Course

Samuel T. Wilkinson, Ibrahim Turkoz, Brian Curcio, Kristin R. Dorsey, Zhiheng Zhang, Christian Edelstein


This document will be available on Sep 17th 2026

Efficacy of Esketamine Nasal Spray Monotherapy for Treatment-Resistant Depression: Post Hoc Analysis by Baseline Disease Severity and Prior Treatment

Mai Himedan, Oliver Lopena, Lisa Lim, Alexis Davis, Ifeanyi Valentine Uche, Dong-Jing Fu, Ibrahim Turkoz, Michael Asbach


This document will be available on Sep 17th 2026

Incremental Healthcare Resource Utilization and Costs Associated With Depression Severity Measured by the Patient Health Questionnaire-9

Dejan Milentijevic, Arthur Voegel, Maryia Zhdanava, Dominic Pilon, Anabelle Tardif-Samson, Yuxi Wang, Brahim Bookhart, Paul E Greenberg


This document will be available on Sep 17th 2026

Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial

Raffaele Migliore, Willie R. Earley, Suresh Durgam, Yifan Mo, Joanna Armas-Datorre, Susan G. Kornstein


This document will be available on Sep 17th 2026

Lumateperone Treatment of Manic Episodes With or Without Mixed Features in Bipolar I Disorder: Results From a Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial

Andrew J. Cutler, Willie R. Earley, Robert Hayes, Changzheng Chen, Hassan Lakkis, Maxine Chen, Michael Thase, David Brown


This document will be available on Sep 17th 2026

Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Samar Madi, Michael Smith, Craig Chepke


This document will be available on Sep 17th 2026

Montgomery-Åsberg Depression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis

Matthew Macaluso, Craig Chepke, Mai Himedan, DJ Fu, Oliver Lopena, Allen Wu, Ibrahim Turkoz, Lilianna Ly, Lisa Lim


This document will be available on Sep 17th 2026

Patient and Healthcare Practitioner Treatment Preferences for Treatment-Resistant Depression

Josh Hamilton, Hui Lu, Laura E. Panattoni, Anup Das, Jennifer A. Whitty, Brahim Bookhart, Dejan Milentijevic, Rakesh Amin


This document will be available on Sep 17th 2026

Patient characteristics, diagnostic history, and treatment journeys among patients with newly diagnosed bipolar disorder

Atreyee Majumder, Chang Xu, Zhiwen Liu, Alex Z. Fu, Brahim Bookhart, Madhav Namjoshi


This document will be available on Sep 17th 2026

Preservation of Cardiometabolic Health During Adjunctive Lumateperone Treatment in Major Depressive Disorder (MDD): A Post Hoc Analysis

Andrew Krystal, C. Neill Epperson, Ibrahim Turkoz, Brian Curcio, Kristin R. Dorsey, Zhiheng Zhang, Christoph U. Correll


This document will be available on Sep 17th 2026

Rapid and Sustained Remission with Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Overview of Remission Rates from Six Clinical Trials

Rakesh Jain, Kristian Dambrino, Mai Himedan, Ibrahim Turkoz, DJ Fu, Lisa Lim, Alexis Davis, Oliver Lopena, Lilianna Ly, Ronaldo Naranjo Jr., Allen Wu


This document will be available on Sep 17th 2026

Real-world Lumateperone Dosing Patterns and Treatment Duration in Bipolar Depression

Madhav Namjoshi, Zhiwen Liu, Zhongyun Zhao, Camilo Obando


This document will be available on Sep 17th 2026

Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials

Zubin Bhagwagar, Suresh Durgam, Willie R. Earley, Changzheng Chen, Tobie Escher, Michael E. Thase


This document will be available on Sep 17th 2026

Total Cost per Remitter of Lumateperone Versus Cariprazine for the Treatment of Major Depressive Disorder in the United States

Eric Wu, Michael K Xu, Jack Eales, Hekun Chen, Zheng-Yi Zhou, Madhav Namjoshi


This document will be available on Sep 17th 2026

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.